Five Prime to Present Clinical Data at 2017 ASCO Annual Meeting
April 20 2017 - 4:10PM
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage
biotechnology company focused on discovering and developing
innovative immuno-oncology protein therapeutics, today announced
that it will feature two clinical poster presentations during the
2017 American Society of Clinical Oncology (ASCO) Annual Meeting,
being held June 2-6, in Chicago.
Abstract Number and Title: #4067, “Updated
antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b
isoform-specific monoclonal antibody, in patients with FGFR2b+
gastric cancer” Poster Session: Gastrointestinal
(Noncolorectal) Cancer Session Date and Time:
Saturday, June 3, 2017, 8 - 11:30 a.m. Location:
Hall A, Poster Board Number: 59 Abstract Number and
Title: #11078, “A phase I/II dose escalation and expansion
study of cabiralizumab (cabira; FPA008), an anti-CSF1R antibody, in
tenosynovial giant cell tumor (TGCT, diffuse pigmented villonodular
synovitis D-PVNS)”Poster Session:
SarcomaSession Date and Time: Sunday, June 4,
2017, 8 – 11:30 a.m.Location: Hall A, Poster Board
Number: 401
About Five Prime Five Prime Therapeutics, Inc.
discovers and develops innovative therapeutics to improve the lives
of patients with serious diseases. Five Prime's comprehensive
discovery platform, which encompasses virtually every medically
relevant extracellular protein, positions it to explore pathways in
cancer, inflammation and their intersection in immuno-oncology, an
area with significant therapeutic potential and a growing focus of
the company's R&D activities. Five Prime has entered into
strategic collaborations with leading global pharmaceutical
companies and has promising product candidates in clinical and late
preclinical development. For more information, please visit
www.fiveprime.com.
Cautionary Note on Forward-looking
StatementsThis press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as "may," "will," "expect," "plan,"
"anticipate," "estimate," "intend" and similar expressions (as well
as other words or expressions referencing future events, conditions
or circumstances) are intended to identify forward-looking
statements. These forward-looking statements are based on Five
Prime's expectations and assumptions as of the date of this press
release. Each of these forward-looking statements involves risks
and uncertainties. Actual results may differ materially from these
forward-looking statements. Factors that may cause actual results
to differ from those expressed or implied in the forward-looking
statements in this press release are discussed in Five Prime's
filings with the U.S. Securities and Exchange Commission, including
the "Risk Factors" contained therein. Except as required by law,
Five Prime assumes no obligation to update any forward-looking
statements contained herein to reflect any change in expectations,
even as new information becomes available.
CONTACTS:
Heather Rowe
Investor Relations
415-365-5737
heather.rowe@fiveprime.com
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From Apr 2024 to May 2024
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From May 2023 to May 2024